Inhibitors/antagonists of TGF-β system in kidney fibrosis

Nephrology Dialysis Transplantation

Volumn 27, Issue 10, 2012, Pages 3686-3691

  Yanagita, Motoko ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bmp antagonist; Bmp7; CKD; fibrosis; TGF

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXY 1 METHYLTETRALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRESOLIMUMAB; GREMLIN; LERDELIMUMAB; METELIMUMAB; OSTEOGENIC PROTEIN 1; OSTEOGENIC PROTEIN 1 ANTAGONIST; OSTEOGENIC PROTEIN 1 STIMULATING AGENT; PIRFENIDONE; PLACEBO; PROTEIN INHIBITOR; RECOMBINANT OSTEOGENIC PROTEIN 1; SMALL INTERFERING RNA; THR 123; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ALPORT SYNDROME; ANEMIA; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; GENE; GENE DELETION; GLAUCOMA SURGERY; GREM1 GENE; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LUPUS ERYTHEMATOSUS NEPHRITIS; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RENAL PROTECTION; REVIEW; SCAR FORMATION; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; USAG 1 GENE;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; FIBROSIS; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84868550831     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs381     Document Type: Review

References (73)

1. Eddy AA, Neilson EG. Chronic kidney disease progression. J Am Soc Nephrol 2006; 17: 2964-2966
2. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696
3. Barnes JL, Glass WF, 2nd. Renal interstitial fibrosis: a critical evaluation of the origin of myofibroblasts. Contrib Nephrol 2011; 169: 73-93
4. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 2011; 121: 468-474
5. Humphreys BD, Lin SL, Kobayashi A et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97
6. Asada N, Takase M, Nakamura J et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011; 121: 3981-3990
7. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol 2005; 289: F227-F234
8. Dussaule JC, Chatziantoniou C. Reversal of renal disease: is it enough to inhibit the action of angiotensin II? Cell Death Differ 2007; 14: 1343-1349
9. Sugimoto H, LeBleu VS, Bosukonda D et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012; 18: 396-404
10. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. Embo J 2000; 19: 1745-1754
11. Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 2008; 13: 4984-4992
12. Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci 2011; 7: 1056-1067
13. Decleves AE, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 2010; 6: 371-380
14. Bottinger EP. TGF-beta in renal injury and disease. Semin Nephrol 2007; 27: 309-320
15. Yang L, Besschetnova TY, Brooks CR et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543, 1p following 143
16. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003; 12: 25-29
17. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146
18. Sharma K, McGowan TA. TGF-beta in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev 2000; 11: 115-123
19. Pohlers D, Brenmoehl J, Loffler I et al. TGF-beta and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 2009; 1792: 746-756
20. Sharma K, Jin Y, Guo J et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-530
21. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020
22. Chen S, Iglesias-de la Cruz MC, Jim B et al. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003; 300: 16-22
23. Benigni A, Zoja C, Corna D et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14: 1816-1824
24. Mead AL, Wong TT, Cordeiro MF et al. Evaluation of anti-TGFbeta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003; 44: 3394-3401
25. Denton CP, Merkel PA, Furst DE et al. Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-333
26. Mathew A, Cunard R, Sharma K. Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol 2011; 170: 217-227
27. RamachandraRao SP, Zhu Y, Ravasi T et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20: 1765-1775
28. Cho ME, Smith DC, Branton MH et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 906-913
29. Sharma K, Ix JH, Mathew AVet al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011; 22: 1144-1151
30. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35-51
31. Nakamura J, Yanagita M. Bmp modulators in kidney disease. Discov Med 2012; 13: 57-63
32. Yanagita M. Antagonists of bone morphogenetic proteins in kidney disease. Curr Opin Investig Drugs 2010; 11: 315-322
33. Luo G, Hofmann C, Bronckers AL et al. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 1995; 9: 2808-2820
34. Dudley AT, Lyons KM, Robertson EJ. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 1995; 9: 2795-2807
35. Vukicevic S, Basic V, Rogic D et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998; 102: 202-214
36. Wang S, Chen Q, Simon TC et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003; 63: 2037-2049
37. Wang S, de Caestecker M, Kopp J et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006; 17: 2504-2512
38. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGFbeta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968
39. Zeisberg M, Bottiglio C, Kumar N et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003; 285: F1060-F1067
40. Sugimoto H, Grahovac G, Zeisberg M et al. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007; 56: 1825-1833
41. Mitu GM, Wang S, Hirschberg R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol 2007; 293: F1641-F1648
42. De Petris L, Hruska KA, Chiechio S et al. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007; 22: 3442-3450
43. Gould SE, Day M, Jones SS et al. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002; 61: 51-60
44. Zhang XL, Selbi W, de la Motte C et al. Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-beta1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol 2005; 16: 79-89
45. Steinbicker AU, Sachidanandan C, Vonner AJ et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 2011; 117: 4915-4923
46. Eddy AA. Ramping up endogenous defences against chronic kidney disease. Nephrol Dial Transplant 2006; 21: 1174-1177
47. Tanaka M, Endo S, Okuda T et al. Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury. Kidney Int 2008; 73: 181-191
48. Leeuwis JW, Nguyen TQ, Chuva de Sousa Lopes SM et al. Direct visualization of Smad1/5/8-mediated transcriptional activity identifies podocytes and collecting ducts as major targets of BMP signalling in healthy and diseased kidneys. J Pathol 2011; 224: 121-132
49. Yanagita M, Oka M, Watabe T et al. USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. Biochem Biophys Res Commun 2004; 316: 490-500
50. Yanagita M, Okuda T, Endo S et al. Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J Clin Invest 2006; 116: 70-79
51. Tanaka M, Asada M, Higashi AY et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest 2010; 120: 768-777
52. Itasaki N, Jones CM, Mercurio S et al. Wise, a context-dependent activator and inhibitor of Wnt signalling. Development 2003; 130: 4295-4305
53. Roxburgh SA, Kattla JJ, Curran SP et al. Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes 2009; 58: 1641-1650
54. Zhang Q, Shi Y, Wada J et al. In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS One 2010; 5: e11709
55. Dionne MS, Skarnes WC, Harland RM. Mutation and analysis of Dan, the founding member of the Dan family of transforming growth factor beta antagonists. Mol Cell Biol 2001; 21: 636-643
56. Ohtori S, Isogai E, Hasue F et al. Reduced inflammatory pain in mice deficient in the differential screening-selected gene aberrative in neuroblastoma. Mol Cell Neurosci 2004; 25: 504-514
57. Chi L, Saarela U, Railo A et al. A secreted BMP antagonist, Cer1, fine tunes the spatial organization of the ureteric bud tree during mouse kidney development. PLoS One 2011; 6: e27676
58. Marques S, Borges AC, Silva AC et al. The activity of the Nodal antagonist Cerl-2 in the mouse node is required for correct L/R body axis. Genes Dev 2004; 18: 2342-2347
59. Dolan V, Murphy M, Sadlier D et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 2005; 45: 1034-1039
60. Mezzano S, Droguett A, Burgos ME et al. Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol Dial Transplant 2007; 22: 1882-1890
61. Michos O, Panman L, Vintersten K et al. Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development 2004; 131: 3401-3410
62. Kassai Y, Munne P, Hotta Y et al. Regulation of mammalian tooth cusp patterning by ectodin. Science 2005; 309: 2067-2070
63. Kramer I, Loots GG, Studer A et al. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010; 25: 178-189
64. Bachiller D, Klingensmith J, Kemp C et al. The organizer factors Chordin and Noggin are required for mouse forebrain development. Nature 2000; 403: 658-661
65. Larman BW, Karolak MJ, Adams DC et al. Chordin-like 1 and twisted gastrulation 1 regulate BMP signaling following kidney injury. J Am Soc Nephrol 2009; 20: 1020-1031
66. Villanueva S, Cespedes C, Gonzalez AA et al. Inhibition of bFGFreceptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 2008; 294: R819-R828
67. Brunet LJ, McMahon JA, McMahon AP et al. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 1998; 280: 1455-1457
68. McMahon JA, Takada S, Zimmerman LB et al. Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. Genes Dev 1998; 12: 1438-1452
69. Zakin L, De Robertis EM. Inactivation of mouse Twisted gastrulation reveals its role in promoting Bmp4 activity during forebrain development. Development 2004; 131: 413-424
70. Nosaka T, Morita S, Kitamura H et al. Mammalian twisted gastrulation is essential for skeleto-lymphogenesis. Mol Cell Biol 2003; 23: 2969-2980
71. Ikeya M, Fukushima K, Kawada M et al. Cv2, functioning as a pro-BMP factor via twisted gastrulation, is required for early development of nephron precursors. Dev Biol 2010; 337: 405-414
72. Ikeya M, Kawada M, Kiyonari H et al. Essential pro-Bmp roles of crossveinless 2 in mouse organogenesis. Development 2006; 133: 4463-4473
73. Lin J, Patel SR, Cheng X et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med 2005; 11: 387-393